| Literature DB >> 30186183 |
Yang Li1, Ying Peng1, Ping Ma1, Hanlin Yang1, Haiyan Xiong1, Mengyue Wang1, Chongsheng Peng1, Pengfei Tu2, Xiaobo Li1.
Abstract
Growing evidence shows that neuropsychiatric disorders, such as depression, are linked with gut microbiome through the gut-brain axis. Cistanches Herba is well known for the treatment of "kidney-yang" deficiency in traditional Chinese medicine (TCM), and has been used for treatment of neurodegenerative diseases in recent years. In this study, chronic unpredictable stress (CUS)-induced depression model was established to explore the impact of Cistanche tubulosa extract (CTE) on behavioral tests, monoamine neurotransmitters and neurotrophic factors in hippocampus and colon, gut microbiota composition, and short-chain fatty acids (SCFAs) production. Moreover, correlation analysis was used to evaluate the functional relationship between altered gut microbiota, changed neurotransmitters and neurotrophins in hippocampus and colon, and disturbed concentration of SCFAs. CTE significantly improved depression-like behaviors in rats under CUS. Brain level of 5-hydroxytryptamine (5-HT) and brain-derived neurotrophic factor (BDNF) expression in CUS rats were restored by CTE. The relative abundance of gut microbiota and the concentrations of acetate and hexanoic acid could also be modulated by CTE treatment. We further showed that the application of CTE in CUS rats led to strong correlation among disrupted gut microbiota composition, hippocampus neurotransmitter levels, and production of neuroactive metabolite SCFAs. Altogether, these results identify CTE as a potential treatment for depressive symptoms by restoring homeostasis of gut microbiota for microbiota-gut-brain axis disorders, opening new avenues in the field of neuropsychopharmacology.Entities:
Keywords: Cistanche tubulosa; antidepressant; chronic unpredictable stress; gut microbiota; microbiota–gut–brain axis
Year: 2018 PMID: 30186183 PMCID: PMC6112285 DOI: 10.3389/fphar.2018.00967
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
chemical composition of C. tubulosa extract.
| Compound category | Percentage of relative content | Constituents |
|---|---|---|
| PhGs | 48.6% | Decaffeoylacteoside |
| Cistantubuloside C1/C2 | ||
| Cistanoside H | ||
| Campneoside II | ||
| Echinacoside | ||
| Isomer of campneoside II | ||
| Poliumoside | ||
| Isopoliumoside | ||
| Cistanoside A | ||
| Tubuloside A | ||
| Acteoside | ||
| Isoacteoside | ||
| Cistanoside C | ||
| 2′-Acetylacteoside | ||
| Osmanthuside B or osmanthuside B6 | ||
| Isocistanoside C | ||
| Tubuloside B | ||
| Osmanthuside B or osmanthuside B6 | ||
| Salsaside F or isomer | ||
| Salsaside F or isomer | ||
| Iridoids and Iridoid glycosides | 6.9% | 8-Epiloganic acid or isomer |
| 8-Epiloganic acid or isomer | ||
| Kankanoside A or isomer | ||
| Kankanoside A or isomer | ||
| Kankanoside N | ||
| Glycosides | Not detect | Kankanose |
| Cistanoside F | ||
| Saccharides | 20.0% | – |
Significantly altered gut microbial taxa at different taxonomic levels in chronic unpredictable stress rats treated with C. tubulosa extract.
| No. | Phylum | Class | Order | Family | Genus | Species |
|---|---|---|---|---|---|---|
| 1 | Bacteroidetes | Bacteroidia | Bacteroidales | Bacteroidaceae | ||
| 2 | Bacteroidetes | Bacteroidia | Bacteroidales | Porphyromonadaceae | ||
| 3 | Bacteroidetes | Bacteroidia | Bacteroidales | [Odoribacteraceae] | ||
| 4 | [Thermi] | Deinococci∗ (↗↘)a | Deinococcales∗ (↗↘)a | Deinococcaceae∗ (↗↘)a | ||
| 5 | Firmicutes | Bacilli | Lactobacillales | Leuconostocaceae | ||
| 6 | Firmicutes | Bacilli | Lactobacillales | Carnobacteriaceae | ||
| 7 | Firmicutes | Clostridia | Clostridiales | Ruminococcaceae | ||
| 8 | Actinobacteria | Actinobacteria | Actinomycetales | Dermabacteraceae |